Our work extends the previous findings by suggesting that (a) ALOX5 upregulation is a common molecular feature in gastrointestinal tract cancers; (b) ALOX5 expression is heterogeneous in gastric cancer patients; and (c) activation of ALOX5‐5‐HETE axis in gastric cancer. Here, ALOX5 is linked to digestive system cancer.